Raymond James & Associates’s Immunomedics Inc IMMU Stock Holding History

Raymond James & Associates’s Portfolio IMMU Stock Details IMMU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-3,455	Closed	-$294K	–	3955
2020 Q3	$294K	Sell	3,455 -5,731	-62%	-$290K	﹤0.01%	2970
2020 Q2	$326K	Buy	+9,186	New	+$269K	﹤0.01%	2870
2019 Q4	–	Sell	-12,171	Closed	-$161K	–	3788
2019 Q3	$161K	Sell	12,171 -690	-5%	-$10.1K	﹤0.01%	3322
2019 Q2	$178K	Sell	12,861 -1,834	-12%	-$27.6K	﹤0.01%	3301
2019 Q1	$282K	Buy	+14,695	New	+$237K	﹤0.01%	3011
2016 Q2	–	Sell	-20,750	Closed	-$52K	–	3117
2016 Q1	$52K	Buy	+20,750	New	+$46.7K	﹤0.01%	2782

Raymond James & Associates's IMMU Position: Q4 2020 in Review

Raymond James & Associates sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 3,455 shares — an estimated $294K sold.

Raymond James & Associates first reported a position in IMMU in Q1 2016 and held it in 6 quarters. The position peaked at $326K in Q2 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.

Raymond James & Associates reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
Raymond James & Associates sold 3,455 Immunomedics Inc shares in Q4 2020, an estimated $294K.
Raymond James & Associates first reported a position in Immunomedics Inc in Q1 2016 and held it in 6 quarters.
Raymond James & Associates's Immunomedics Inc position peaked at $326K in Q2 2020.
0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.

Based on Raymond James & Associates's 13F filing for Q4 2020, filed 12 Feb 2021.